Oct. 27 at 3:58 PM
Prenetics Global Ltd shares fell Monday after the health sciences company announced a
$48 million public offering. The deal includes nearly 3 million Class A ordinary shares along with an equal number of Class A and Class B warrants. The combined offering price was set at
$16.08 per share or pre-funded unit. Class A warrants are exercisable at
$24.12 per share (50% premium), and Class B warrants at
$32.16 (100% premium), both exercisable immediately for five years. Proceeds will fund global expansion of the IM8 product line and strategic Bitcoin accumulation as part of a “health and wealth” strategy. Dominari Securities acted as sole placement agent; the offering is expected to close October 28, 2025. The sharp share drop suggests investor concern over potential dilution despite growth plans.
$PRE